vs

Side-by-side financial comparison of AVINO SILVER & GOLD MINES LTD (ASM) and RECURSION PHARMACEUTICALS, INC. (RXRX). Click either name above to swap in a different company.

RECURSION PHARMACEUTICALS, INC. is the larger business by last-quarter revenue ($35.5M vs $21.0M, roughly 1.7× AVINO SILVER & GOLD MINES LTD). AVINO SILVER & GOLD MINES LTD runs the higher net margin — 36.6% vs -304.2%, a 340.8% gap on every dollar of revenue. On growth, RECURSION PHARMACEUTICALS, INC. posted the faster year-over-year revenue change (681.7% vs 44.0%). Over the past eight quarters, RECURSION PHARMACEUTICALS, INC.'s revenue compounded faster (60.5% CAGR vs 51.1%).

Avino Silver & Gold Mines Ltd is a Canada-based mining company engaged in the exploration, development, and production of precious and base metals, primarily silver, gold, and copper. It operates its flagship Avino Mine property in Durango, Mexico, with its metal products supplied to global industrial and commodity markets.

Recursion Pharmaceuticals is a clinical-stage biotechnology company that combines artificial intelligence and large-scale high-throughput biological experimentation to discover and develop innovative therapies for rare diseases, oncology, inflammatory disorders, and other areas of unmet medical need. It primarily operates in North America and partners with global biopharmaceutical firms to advance its robust therapeutic pipeline.

ASM vs RXRX — Head-to-Head

Bigger by revenue
RXRX
RXRX
1.7× larger
RXRX
$35.5M
$21.0M
ASM
Growing faster (revenue YoY)
RXRX
RXRX
+637.8% gap
RXRX
681.7%
44.0%
ASM
Higher net margin
ASM
ASM
340.8% more per $
ASM
36.6%
-304.2%
RXRX
Faster 2-yr revenue CAGR
RXRX
RXRX
Annualised
RXRX
60.5%
51.1%
ASM

Income Statement — Q3 FY2025 vs Q4 FY2025

Metric
ASM
ASM
RXRX
RXRX
Revenue
$21.0M
$35.5M
Net Profit
$7.7M
$-108.1M
Gross Margin
47.1%
59.8%
Operating Margin
-304.8%
Net Margin
36.6%
-304.2%
Revenue YoY
44.0%
681.7%
Net Profit YoY
558.9%
39.6%
EPS (diluted)
$0.05
$-0.17

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
ASM
ASM
RXRX
RXRX
Q4 25
$35.5M
Q3 25
$21.0M
$5.2M
Q2 25
$21.8M
$19.2M
Q1 25
$18.8M
$14.7M
Q4 24
$4.5M
Q3 24
$14.6M
$26.1M
Q2 24
$14.8M
$14.4M
Q1 24
$12.4M
$13.8M
Net Profit
ASM
ASM
RXRX
RXRX
Q4 25
$-108.1M
Q3 25
$7.7M
$-162.3M
Q2 25
$2.9M
$-171.9M
Q1 25
$5.6M
$-202.5M
Q4 24
$-178.9M
Q3 24
$1.2M
$-95.8M
Q2 24
$1.2M
$-97.5M
Q1 24
$599.0K
$-91.4M
Gross Margin
ASM
ASM
RXRX
RXRX
Q4 25
59.8%
Q3 25
47.1%
-183.8%
Q2 25
46.9%
-4.9%
Q1 25
56.1%
-48.0%
Q4 24
-181.4%
Q3 24
39.1%
53.7%
Q2 24
31.8%
36.2%
Q1 24
18.9%
19.1%
Operating Margin
ASM
ASM
RXRX
RXRX
Q4 25
-304.8%
Q3 25
-3327.6%
Q2 25
-916.8%
Q1 25
-1297.9%
Q4 24
-4042.4%
Q3 24
-377.1%
Q2 24
-697.4%
Q1 24
-698.4%
Net Margin
ASM
ASM
RXRX
RXRX
Q4 25
-304.2%
Q3 25
36.6%
-3135.3%
Q2 25
13.1%
-894.2%
Q1 25
29.8%
-1373.3%
Q4 24
-3935.5%
Q3 24
8.0%
-367.5%
Q2 24
8.4%
-676.6%
Q1 24
4.8%
-662.4%
EPS (diluted)
ASM
ASM
RXRX
RXRX
Q4 25
$-0.17
Q3 25
$0.05
$-0.36
Q2 25
$0.02
$-0.41
Q1 25
$0.04
$-0.50
Q4 24
$-0.56
Q3 24
$0.01
$-0.34
Q2 24
$0.01
$-0.40
Q1 24
$0.00
$-0.39

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
ASM
ASM
RXRX
RXRX
Cash + ST InvestmentsLiquidity on hand
$57.3M
$743.3M
Total DebtLower is stronger
$9.6M
Stockholders' EquityBook value
$182.1M
$1.1B
Total Assets
$221.9M
$1.5B
Debt / EquityLower = less leverage
0.01×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
ASM
ASM
RXRX
RXRX
Q4 25
$743.3M
Q3 25
$57.3M
$659.8M
Q2 25
$37.3M
$525.1M
Q1 25
$26.6M
$500.5M
Q4 24
$594.4M
Q3 24
$7.8M
$427.6M
Q2 24
$5.3M
$474.3M
Q1 24
$3.5M
$296.3M
Total Debt
ASM
ASM
RXRX
RXRX
Q4 25
$9.6M
Q3 25
$11.9M
Q2 25
$14.2M
Q1 25
$16.4M
Q4 24
$19.0M
Q3 24
$20.5M
Q2 24
$22.9M
Q1 24
Stockholders' Equity
ASM
ASM
RXRX
RXRX
Q4 25
$1.1B
Q3 25
$182.1M
$1.0B
Q2 25
$144.8M
$919.1M
Q1 25
$132.3M
$933.9M
Q4 24
$1.0B
Q3 24
$114.5M
$524.6M
Q2 24
$112.2M
$584.4M
Q1 24
$107.8M
$401.2M
Total Assets
ASM
ASM
RXRX
RXRX
Q4 25
$1.5B
Q3 25
$221.9M
$1.4B
Q2 25
$174.7M
$1.3B
Q1 25
$157.7M
$1.3B
Q4 24
$1.4B
Q3 24
$135.4M
$726.5M
Q2 24
$133.7M
$775.9M
Q1 24
$128.6M
$557.8M
Debt / Equity
ASM
ASM
RXRX
RXRX
Q4 25
0.01×
Q3 25
0.01×
Q2 25
0.02×
Q1 25
0.02×
Q4 24
0.02×
Q3 24
0.04×
Q2 24
0.04×
Q1 24

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
ASM
ASM
RXRX
RXRX
Operating Cash FlowLast quarter
$8.3M
$-46.1M
Free Cash FlowOCF − Capex
$-47.3M
FCF MarginFCF / Revenue
-133.1%
Capex IntensityCapex / Revenue
3.5%
Cash ConversionOCF / Net Profit
1.08×
TTM Free Cash FlowTrailing 4 quarters
$-378.3M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
ASM
ASM
RXRX
RXRX
Q4 25
$-46.1M
Q3 25
$8.3M
$-117.4M
Q2 25
$8.3M
$-76.4M
Q1 25
$758.0K
$-132.0M
Q4 24
$-115.4M
Q3 24
$4.1M
$-59.2M
Q2 24
$1.1M
$-82.2M
Q1 24
$2.3M
$-102.3M
Free Cash Flow
ASM
ASM
RXRX
RXRX
Q4 25
$-47.3M
Q3 25
$-117.6M
Q2 25
$-79.6M
Q1 25
$-133.8M
Q4 24
$-116.7M
Q3 24
$-63.8M
Q2 24
$-83.4M
Q1 24
$-109.0M
FCF Margin
ASM
ASM
RXRX
RXRX
Q4 25
-133.1%
Q3 25
-2272.5%
Q2 25
-413.9%
Q1 25
-907.4%
Q4 24
-2567.7%
Q3 24
-244.6%
Q2 24
-578.5%
Q1 24
-789.9%
Capex Intensity
ASM
ASM
RXRX
RXRX
Q4 25
3.5%
Q3 25
4.7%
Q2 25
16.4%
Q1 25
12.4%
Q4 24
28.6%
Q3 24
17.5%
Q2 24
8.2%
Q1 24
48.2%
Cash Conversion
ASM
ASM
RXRX
RXRX
Q4 25
Q3 25
1.08×
Q2 25
2.92×
Q1 25
0.13×
Q4 24
Q3 24
3.55×
Q2 24
0.87×
Q1 24
3.92×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons